Teicoplanin: an alternative drug for the treatment of COVID-19?

Sophie Alexandra Baron, Christian Devaux, Philippe Colson, Didier Raoult, Jean-Marc Rolain, Sophie Alexandra Baron, Christian Devaux, Philippe Colson, Didier Raoult, Jean-Marc Rolain

Abstract

In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.

Keywords: COVID-19; Drug repurposing; SARS-CoV-2; Teicoplanin.

Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

References

    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
    1. Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105924.
    1. Devaux C.A., Rolain J.-M., Colson P., Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Forthcoming.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Colson P., Rolain J.-M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105923.
    1. Ko W.-C., Rolain J.-M., Lee N.-Y., Chen P.-L., Huang C.-T., Lee P.-I. Remdesivir for SARS-CoV-2 pneumonia. Int J Antimicrob Agents. 2020 Forthcoming.
    1. Zhang J., Ma X., Yu F., Liu J., Zou F., Pan T. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020 Feb 13 doi: 10.1101/2020.02.05.935387.
    1. Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) J Biol Chem. 2016;291:9218–9232. doi: 10.1074/jbc.M116.716100.
    1. Colson P., Raoult D. Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents. 2016;48:349–352. doi: 10.1016/j.ijantimicag.2016.07.004.
    1. Pan T., Zhou N., Zhang H. WIPO PatentScope; 2015. Use of teicoplanin anti-Middle East respiratory syndrome coronavirus. Publication number: WO/2016/201692. [accessed 14 March 2020]

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere